Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus R-GemOx in Relapsed/Refractory DLBCL
NCT04659434Phase 2Not yet recruiting
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in diffuse large B-cell lymphoma (DLBCL). Planned start Dec 2020; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04659434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659434.